HIV-1非M组体外对比克替拉韦和卡博特韦的表型敏感性
该研究对41株HIV-1/O临床分离株及2株HIV-1/N和1株HIV-1/P进行体外表型研究,评估比克替拉韦和卡博特韦的敏感性。结果显示非M组株对两药总体敏感,IC50与HIV-1/M无差异,但两药IC50在全面板中存在显著差异(P<0.001)。
要点
- HIV-1非M组株对BIC和CAB的体外IC50与M组无显著差异。
- BIC与CAB的IC50值在全面板中存在显著差异(P<0.001)。
- 结果支持非M组感染者使用INSTIs,但需临床数据确认。
核心结论
- 非M组HIV-1株对BIC和CAB体外总体敏感,与M组无差异,但BIC与CAB的IC50存在显著差异。
研究设计与样本
- 体外表型研究,纳入41株HIV-1/O、2株HIV-1/N和1株HIV-1/P临床分离株。
主要发现
- HIV-1/M的IC50均值(范围)为BIC 1.86(0.93-4.12)nM、CAB 5.24(1.76-12.41)nM。
- HIV-1/non-M的IC50均值(范围)为BIC 2.17(0.03-9.47)nM、CAB 4.88(0.02-15.64)nM。
- 全面板中BIC与CAB的IC50值差异显著(P<0.001)。
临床怎么用
- 提示BIC和CAB可用于HIV-1非M组感染者的临床治疗,但需临床数据进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: HIV-1 group O (HIV-1/O) is one of the four HIV-1 groups and is endemic in Cameroon, representing 1% of HIV-1 infections in the population. Around 50% of the strains of this group naturally show a mutation (Y181C) providing them with resistance to NNRTIs and making therapeutic management more difficult. Today, the WHO recommends the use of integrase strand transfer inhibitors (INSTIs) as first-line treatment. Bictegravir and cabotegravir are the two most recent INSTIs. Because of the genetic polymorphism of HIV-1/O, studies are required to evaluate their phenotypic susceptibility to these two drugs. PATIENTS AND METHODS: We performed a phenotypic study on a large panel including 41 HIV-1/O clinical isolates and other rare non-group M HIV-1 (2 HIV-1/N and 1 HIV-1/P) to evaluate in vitro susceptibility to bictegravir and cabotegravir. RESULTS: The results showed an overall susceptibility of non-group M strains to the two drugs compared with HIV-1 group M. There was no difference between the mean (min-max) IC50 of HIV-1/M [1.86 (0.93-4.12) and 5.24 (1.76-12.41) nM for bictegravir and cabotegravir, respectively] and HIV-1/non-M [2.17 (0.03-9.47) and 4.88 (0.02-15.64) nM for bictegravir and cabotegravir, respectively]. However, we found a significant difference between IC50 values for bictegravir and cabotegravir in the whole panel (P value < 0.001). CONCLUSIONS: This study has shown encouraging results regarding the clinical use of these drugs in HIV-1/non-M-infected patients, which will need to be confirmed with clinical data.
引用
- Martin C, Gracias S, Charpentier C, et al. HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir. J Antimicrob Chemother. 2021. PMID: 34151963. doi:10.1093/jac/dkab196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。